Corcept executive exercises options and sells shares

Q: What did Corcept Therapeutics (CORT) executive William Guyer report on this Form 4?

William Guyer, Chief Development Officer, exercised stock options for 16,300 shares at $21.65 and sold 16,300 common shares in market transactions on 2026-08-10, all under a pre-arranged Rule 10b5-1 trading plan.

Q: How many Corcept Therapeutics (CORT) options did William Guyer exercise and what remains?

Guyer exercised 16,300 stock options with a $21.65 exercise price on 2026-08-10. After this transaction, the filing reports he held 110,000 options under that award, which is described as fully exercisable as of the transaction date.

Q: At what prices did William Guyer sell Corcept Therapeutics (CORT) shares?

He sold 11,530 shares at a weighted average $113.1772, with individual prices from $112.80 to $113.75, and 4,770 shares at a weighted average $114.0371, with prices ranging from $113.98 to $114.24 per share.

Q: What does the Form 4 say about William Guyer’s remaining Corcept Therapeutics (CORT) equity awards?

The filing notes he holds 110,000 options under the exercised grant, fully exercisable until 2031-09-01, and unvested restricted stock awards totaling 1,599 shares that will vest one year after each grant date if service conditions are satisfied.

Q: How were weighted average prices disclosed for William Guyer’s Corcept (CORT) stock sales?

For each sale line, the Form 4 gives a weighted average sale price and states the actual price ranges. Investors can request from Corcept the exact number of shares sold at each individual sale price within those ranges.

Corcept Therapeutics Chief Development Officer William Guyer reported an options exercise and related sales.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Corcept Therapeutics Chief Development Officer William Guyer reported an options exercise and related sales. On 2026-08-10, he exercised a stock option for 16,300 shares of common stock at an exercise price of $21.65 per share, leaving 110,000 options outstanding under that award, which is fully exercisable. The same day, he acquired 16,300 common shares through the exercise and sold 11,530 shares at a weighted average of $113.1772 (actual prices from $112.80 to $113.75) and 4,770 shares at a weighted average of $114.0371 (actual prices from $113.98 to $114.24). The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2024, and his reported holdings include unvested restricted stock awards scheduled to vest on their one-year anniversaries if service conditions are met.

Insider Trade Summary 10b5-1

Exercise and Sale: 16,300 shares ($1.50M approx. pre-tax spread)

Exercise and Sale 4 txns

Insider Guyer William

Role Chief Development Officer

Sold 16,300 shs ($1.85M)

Approx. gross sale proceeds $1.85M

Approx. exercise cost $353K

Approx. pre-tax spread $1.50M

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) ^F5	16,300	$0.00	$0.00
Exercise	Common Stock ^F1	16,300	$21.65	$353K
Sale	Common Stock ^{F2, F3, F1}	11,530	$113.1772	$1.30M
Sale	Common Stock ^{F2, F4, F1}	4,770	$114.0371	$544K

Holdings After Transaction: Stock Option (right to buy) — 110,000 contracts (Direct); Common Stock — 3,985 shares (Direct)

Footnotes (5)

F1. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.
F3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.80 to $113.75 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.98 to $114.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F5. Fully exercisable.

Key Figures

Options exercised: 16,300 shares Option exercise price: $21.65 per share Options remaining: 110,000 shares +5 more

8 metrics

Options exercised 16,300 shares Stock option (right to buy) exercised on 2026-08-10

Option exercise price $21.65 per share Conversion or exercise price of stock option exercised

Options remaining 110,000 shares Stock options reported as beneficially owned after the exercise

Shares sold (first block) 11,530 shares at $113.1772 Weighted average sale price; individual prices $112.80–$113.75

Shares sold (second block) 4,770 shares at $114.0371 Weighted average sale price; individual prices $113.98–$114.24

10b5-1 plan adoption date November 27, 2024 Plan governing the 2026-08-10 sale transactions

Option expiration date 2031-09-01 Expiration date of the exercised stock option award

Unvested restricted stock 1,599 shares 224 + 498 + 877 shares underlying unvested restricted stock awards

Key Terms

Rule 10b5-1 plan, weighted average sale price, restricted stock awards, Stock Option (right to buy), +1 more

5 terms

Rule 10b5-1 plan financial

"This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted average sale price financial

"Represents the weighted average sale price for the entire number of shares sold"

restricted stock awards financial

"Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

Stock Option (right to buy) financial

"security_title": "Stock Option (right to buy)""

fully exercisable financial

"Fully exercisable."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Corcept Therapeutics (CORT) executive William Guyer report on this Form 4?

William Guyer, Chief Development Officer, exercised stock options for 16,300 shares at $21.65 and sold 16,300 common shares in market transactions on 2026-08-10, all under a pre-arranged Rule 10b5-1 trading plan.

How many Corcept Therapeutics (CORT) options did William Guyer exercise and what remains?

Guyer exercised 16,300 stock options with a $21.65 exercise price on 2026-08-10. After this transaction, the filing reports he held 110,000 options under that award, which is described as fully exercisable as of the transaction date.

At what prices did William Guyer sell Corcept Therapeutics (CORT) shares?

He sold 11,530 shares at a weighted average $113.1772, with individual prices from $112.80 to $113.75, and 4,770 shares at a weighted average $114.0371, with prices ranging from $113.98 to $114.24 per share.

Was William Guyer’s Corcept Therapeutics (CORT) trading under a Rule 10b5-1 plan?

Yes. A footnote states the reported sale transactions were made pursuant to a Rule 10b5-1 trading plan adopted by William Guyer on November 27, 2024, which was in effect at the time of the 2026-08-10 trades.

What does the Form 4 say about William Guyer’s remaining Corcept Therapeutics (CORT) equity awards?

The filing notes he holds 110,000 options under the exercised grant, fully exercisable until 2031-09-01, and unvested restricted stock awards totaling 1,599 shares that will vest one year after each grant date if service conditions are satisfied.

How were weighted average prices disclosed for William Guyer’s Corcept (CORT) stock sales?

For each sale line, the Form 4 gives a weighted average sale price and states the actual price ranges. Investors can request from Corcept the exact number of shares sold at each individual sale price within those ranges.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/12/2026 - 04:26 PM Accepted by SEC EDGAR 08/12/2026 - 04:26 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guyer William

(Last)

(First)

(Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY

CALIFORNIA

94065

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/10/2026		M		16,300	A	$21.65	20,285⁽¹⁾	D
Common Stock	08/10/2026		S⁽²⁾		11,530	D	$113.1772⁽³⁾	8,755⁽¹⁾	D
Common Stock	08/10/2026		S⁽²⁾		4,770	D	$114.0371⁽⁴⁾	3,985⁽¹⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$21.65	08/10/2026		M			16,300	⁽⁵⁾	09/01/2031	Common Stock	16,300	$0.00	110,000	D

Explanation of Responses:

1. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

2. This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on November 27, 2024 in effect at the time of this transaction.

3. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.80 to $113.75 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

4. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.98 to $114.24 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

5. Fully exercisable.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR